JunHe Advises Xiao Fang Pharmaceutical on its Listing on m88 casino review Main Board of m88 casino review Shanghai Stock Exchange

On August 26, 2024, Shanghai Xiao Fang Pharmaceutical Co., Ltd. (603207) ("XF Pharmaceutical") was listed on m88 casino review Main Board of m88 casino review Shanghai Stock Exchange. m88 casino review company issued 40 million new shares at RMB 12.47 per share in m88 casino review IPO, raising approximately RMB 500 million. m88 casino review stock price surged more than 200% on m88 casino review first day.

Established in August 1993, XF Pharmaceutical specializes in m88 casino review research, production and sales of topical medicines. m88 casino review company's mission is to provide a wide range of high-quality, effective topical medications that families can rely on. m88 casino review "Xinlong" trademark, created and used by XF Pharmaceutical, is a well-known brand in Shanghai with high market recognition. m88 casino review company's various topical medication products have held a leading market share in China for many years.

As m88 casino review issuer's legal counsel, JunHe provided comprehensive legal services for XF Pharmaceutical's IPO. We assisted m88 casino review company in addressing significant legal matters such as continuous legal compliance, equity incentives, financing, shareholding reform, and IPO application. m88 casino review listing process witnessed major reforms in China's policies on m88 casino review capital market.

In March 2023, a registration-based reform was implemented and XF Pharmaceutical became one of m88 casino review first companies to transfer from m88 casino review China Securities Regulatory Commission to m88 casino review Shanghai Stock Exchange for review.

From August 2023, IPO reviews were gradually tightened in m88 casino review domestic capital market, imposing higher requirements on companies intending to go public. XF Pharmaceutical became one of m88 casino review first companies to receive official IPO registration approval from m88 casino review China Securities Regulatory Commission after m88 casino review policy tightening.

In March 2024, m88 casino review China Securities Regulatory Commission issued a series of new regulations, including m88 casino review Opinions on Tightening Scrutiny Over Initial Public Offerings and Improving m88 casino review Quality of Listed Companies from m88 casino review Source (Trial Implementation) (commonly known as m88 casino review "315 New Rules"). In April 2024, m88 casino review State Council issued Several Opinions on Strengm88 casino reviewning Regulation, Preventing Risks, and Promoting High-Quality Development of m88 casino review Capital Market (commonly known as m88 casino review "New Nine Articles"). XF Pharmaceutical was m88 casino review first company in m88 casino review pharmaceutical sector to go public after m88 casino review implementation of m88 casino reviewse new regulations.

Throughout m88 casino reviewse policy reforms, JunHe provided effective legal analysis and feedback in accordance with m88 casino reviewse new policies, adjustments and regulatory concerns. Our meticulous and professional legal services earned high recognition from XF Pharmaceutical.

m88 casino review JunHe team was led by partnerwith support from partnerm88 bonus 君合法评,君合人文,京公网安备11010102005423号for m88 casino review internal control.